Comparative Pharmacology
Head-to-head clinical analysis: CANDESARTAN CILEXETIL HYDROCHLOROTHIAZIDE versus ZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANDESARTAN CILEXETIL HYDROCHLOROTHIAZIDE versus ZIDE.
CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE vs ZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Candesartan cilexetil is a prodrug that is hydrolyzed to candesartan, an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor, inhibiting vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride and increasing excretion of water, sodium, chloride, potassium, and bicarbonate.
Initial dose: 1 tablet (candesartan cilexetil 16 mg / hydrochlorothiazide 12.5 mg) orally once daily; titrate based on response to maximum dose of 32 mg/25 mg once daily.
10 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateBendroflumethiazide + Digoxin
"The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Digoxin."
Clinical Note
moderateMethyclothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digoxin."
Clinical Note
moderateHydrochlorothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digoxin."
Clinical Note
moderateCandesartan: ~9 hours (terminal); Hydrochlorothiazide: 6–15 hours (terminal). Both support once-daily dosing.
6-8 hours in normal renal function; prolonged to 20-40 hours in severe renal impairment (eGFR <30 mL/min).
Candesartan: 33% renal, 67% biliary/fecal. Hydrochlorothiazide: ≥95% renal (unchanged).
Renal: 70% unchanged; Biliary/fecal: 30% (as metabolites and parent compound).
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic
Hydroflumethiazide + Digoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digoxin."